We are live on ! Find out more
DNA.WS

Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share

Delisted

DNA.WS was delisted on the 3rd of September, 2024.

28 hedge funds and large institutions have $249K invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2828 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

67% less capital invested

Capital invested by funds: $758K → $249K (-$509K)

Holders
28
Holders Change
Holders Change %
0%
% of All Funds
0.4%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
3
Increased
4
Reduced
5
Closed
3
Calls
$11K
Puts
Net Calls
+$11K
Net Calls Change
-$23K
Name Holding Trade Value Shares
Change
Change in
Stake
C
26
Chescapmanager
Maryland
-$9.32K -103,521 Closed
CIBC Private Wealth Group
27
CIBC Private Wealth Group
Georgia
-$4.38K -50,000 Closed
Osaic Holdings
28
Osaic Holdings
Arizona
-$94 -1,039 Closed
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
-$30 -560 -70%

DNA.WS Hedge Fund Activity: Q2 2024 in Review

28 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q2 2024, worth a combined $249K — down 67% from $758K a quarter earlier.

Fund positioning in DNA.WS was balanced in Q2 2024: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 5 trimmed.

The largest buyer was Cowen and Company, adding an estimated $68.8K. The largest seller was Morgan Stanley, cutting an estimated $38.6K.

  • 28 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $249K of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q2 2024, down 67% quarter-over-quarter.
  • 3 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q2 2024 and 3 closed out, a net change of 0 holders.
  • The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q2 2024 was Cowen and Company, an estimated $68.8K added.
  • The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q2 2024 was Morgan Stanley, an estimated $38.6K sold.

Based on aggregated 13F filings for Q2 2024.